Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$12.1M | -$39.2M | -$78.9M | -$90.3M | -$52.0M | -$34.6M | -$57.3M | -$58.1M |
| Net income | -$12.5M | -$37.0M | -$76.8M | -$89.9M | -$51.7M | -$31.4M | -$56.8M | -$84.0M |
| EPS (diluted) | -$3.71 | -$1.94 | -$2.63 | -$3.03 | -$1.54 | -$0.84 | -$1.31 | -$1.68 |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$11.7M | -$33.3M | -$50.8M | -$62.9M | -$44.0M | -$18.3M | -$31.9M | -$41.4M |
| Capital expenditures | $212K | $55.0K | $52.0K | $180K | $133K | $160K | $257K | $352K |
| Free cash flow | -$11.9M | -$33.3M | -$50.9M | -$63.1M | -$44.2M | -$18.5M | -$32.2M | -$41.8M |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $24.9M | $51.2M | $66.8M | $69.7M | $44.6M | $20.8M | $6.21M | $5.81M |
| Total assets | $72.9M | $124M | $189M | $133M | $104M | $168M | $114M | $93.5M |
| Total liabilities | $1.46M | $8.89M | $17.2M | $14.6M | $3.32M | $82.8M | $84.3M | $129M |
| Long-term debt | — | — | — | — | $0.00 | $13.4M | $14.3M | $0.00 |
| Shareholders' equity | -$32.6M | $115M | $172M | $119M | $101M | $85.1M | $30.1M | -$35.7M |
| Retained earnings | -$32.8M | -$69.8M | -$147M | -$237M | -$288M | -$320M | -$376M | -$460M |
| Shares (wtd avg diluted) | 3.41M | 26.9M | 29.5M | 29.7M | 33.5M | 37.2M | 43.3M | 50.1M |
Every figure is extracted from Quince Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.